You are way off. The focus will be on Spontan and Roxus. The new product was already in development so would have been included in last quarter's cash burn. At that rate, they had 32.7mill in cash and 28 quarters (7 years) of funding. Bringing Roxus to market and moving through FDA approval process will reduce that 7 years of funding to maybe 2 years (just an educated guess) but an imminent cr makes no sense. This is not shooting you down. It's just showing and discussing the numbers.
LTP Price at posting:
30.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)